Roche
1H Revenue: 30.7 billion CHF (+5%)
Net Earnings: 8.2 billion CHF (-3%)
Comments: Pharmaceutical Division sales were 21.7 billion CHF down 3. While sales in the first quarter were still strongly affected by COVID-19 (-9%), the second quarter showed signs of recovery in some regions (+4%). The ongoing impact from biosimilars, particularly in the U.S., resulted in a sales decrease of CHF 2.8 billion, however newly launched medicines (+30%) helped offset continued impact from biosimilars. In the first six months, new medicines generated sales of over CHF 11 billion, contributing more than 50% to the division’s total sales.

Ocrevus sales were 2.4 billion CHF, up 23%. Perjeta sales were up 5% to nearly 2.0 billion CHF. Avastin sales were down 40% to 1.6 billion CHF. Actemra/RoActemra sales were up 17% to 1.6 billion CHF. Tecentriq sales were up 29% to 1.6 billion CHF. Herceptin sales were down 35% to 1.4 billion CHF. Hemlibra sales were up 45% to 1.4 billion CHF. MabThera/Rituxan sales were down 41% to 1.4 billion CHF. Kadcyla sales were up 19% to 959 billion CHF.

COVID-19: Additional positive study results for antibody combination Ronapreve (co-developed with Regeneron) and AT-527 (co-developed with Atea); Japan becomes first country to approve Ronapreve for the treatment of mild to moderate COVID-19; FDA Emergency Use Authorization for Actemra/RoActemra.

Diagnostics Division sales grew 49% due to high demand for COVID-19 tests and strong momentum in routine testing. In April, Roche acquired the U.S. company GenMark Diagnostics for $1.9 billion. GenMark’s technology detects a wide range of pathogens from a single patient sample, expanding Roche’s molecular lab portfolio.

Read Contract Pharma’s Top Companies Report on Roche.